Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecu...

Full description

Saved in:
Bibliographic Details
Main Authors: Gotlib, Jason, Berubé, Caroline, Growney, Joseph D., Chen, Ching-Cheng, George, Tracy I., Williams, Christopher, Kajiguchi, Tomohiro, Ruan, Jia, Lilleberg, Stan L., Durocher, Jeffrey A., Lichy, Jack H., Wang, Yanfeng, Cohen, Pamela S., Arber, Daniel A., Heinrich, Michael C., Neckers, Len, Galli, Stephen J., Gilliland, D. Gary, Coutré, Steven E.
Format: Artigo
Language:Inglês
Published: The American Society of Hematology 2005
Subjects:
Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895309/
https://ncbi.nlm.nih.gov/pubmed/15972446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-04-1568
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items